Germany-based CureVac has dismissed speculation that it might be the subject of a takeover bid, saying it was focusing its attention on using its messenger RNA (mRNA) technology to develop a candidate vaccine to prevent infections from the coronavirus 2019-nCoV. “Internal efforts are focused on the development of a coronavirus vaccine with the goal to reach, help and to protect people and patients worldwide,” the company said in a statement on 15 March.
